27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) fell 1.1% in after-market trading after the company reported Q4 results.
Quarterly Results
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Earnings per share rose 47.65% year over year to $2.51, which missed the estimate of $2.59.
Revenue of $1,628,000,000 rose by 29.51% year over year, which beat the estimate of $1,580,000,000.
Guidance
Earnings guidance hasn't been issued by the company for now.
Revenue guidance hasn't been issued by the company for now.
Conference Call Details
Want Private Access to Benzinga Analyst?
Check out the latest strategies our team of experts are using every week so that you can always adapt to the market like the pros!—Get FULL Access to This Week's Webinar Here.
Date: Feb 01, 2021
Time: 04:30 PM
ET Webcast URL: https://event.webcasts.com/starthere.jsp?ei=1422591&tp_key=ff479c3073
Technicals
52-week high: $306.08
52-week low: $197.47
Price action over last quarter: Up 8.71%
Company Overview
Vertex Pharmaceuticals discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex's pipeline also includes therapies for cancer, pain, inflammatory diseases, influenza, and other rare diseases.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.